Literature DB >> 29436385

Cholesterol efflux capacity does not associate with coronary calcium, plaque vulnerability, and telomere length in healthy octogenarians.

Francesca Zimetti1, Wladimir M Freitas2, Alessandra M Campos2, Mauricio Daher2, Maria Pia Adorni1, Franco Bernini1, Andrei C Sposito3, Ilaria Zanotti4.   

Abstract

Several studies have revealed that traditional risk factors are less effective in predicting CVD risk in the elderly, suggesting the need to identify new biomarkers. Here, we evaluated the association between serum cholesterol efflux capacity (CEC), an atheroprotective property of HDL recently identified as a novel marker of CVD risk, and atherosclerotic burden in a cohort of very old, healthy individuals. Serum CEC values were not significantly correlated either with calcium score or with markers of vulnerable plaque, such as positive remodeling, hypodensity, spotty calcification, or napking-ring sign. In addition, no association was detected between CEC and telomere length, a marker of biological aging that has been linked to atherosclerosis extent. Interestingly, elderly subjects presented a remarkably higher CEC (+30.2%; P < 0.0001) compared with values obtained from a cohort of sex-matched, cardiovascular event-free, middle-aged individuals. In conclusion, serum CEC is not related to traditional risk factors in very old, cardiovascular event-free subjects, but has significantly higher values compared with a healthy, younger population. Whether this improved HDL functionality may represent a protective factor in CVD onset must be established in future studies.
Copyright © 2018 by the American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  aging; atherosclerosis; heart; high density lipoprotein; lipoproteins; vascular biology

Mesh:

Substances:

Year:  2018        PMID: 29436385      PMCID: PMC5880496          DOI: 10.1194/jlr.P079525

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  49 in total

Review 1.  The Brisighella Heart Study: an interim report.

Authors:  G C Descovich
Journal:  Eur Heart J       Date:  1990-12       Impact factor: 29.983

2.  Role of Coronary Artery Calcium Score of Zero and Other Negative Risk Markers for Cardiovascular Disease: The Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Michael J Blaha; Miguel Cainzos-Achirica; Philip Greenland; John W McEvoy; Ron Blankstein; Matthew J Budoff; Zeina Dardari; Christopher T Sibley; Gregory L Burke; Richard A Kronmal; Moyses Szklo; Roger S Blumenthal; Khurram Nasir
Journal:  Circulation       Date:  2016-01-22       Impact factor: 29.690

Review 3.  Cholesterol efflux capacity, macrophage reverse cholesterol transport and cardioprotective HDL.

Authors:  Patrick M Hutchins; Jay W Heinecke
Journal:  Curr Opin Lipidol       Date:  2015-10       Impact factor: 4.776

4.  Impact of statins on serial coronary calcification during atheroma progression and regression.

Authors:  Rishi Puri; Stephen J Nicholls; Mingyuan Shao; Yu Kataoka; Kiyoko Uno; Samir R Kapadia; E Murat Tuzcu; Steven E Nissen
Journal:  J Am Coll Cardiol       Date:  2015-04-07       Impact factor: 24.094

Review 5.  Experimental models for the investigation of high-density lipoprotein-mediated cholesterol efflux.

Authors:  Carlos G Santos-Gallego; Chiara Giannarelli; Juan José Badimón
Journal:  Curr Atheroscler Rep       Date:  2011-06       Impact factor: 5.113

6.  Napkin-ring sign on coronary CT angiography for the prediction of acute coronary syndrome.

Authors:  Kenichiro Otsuka; Shota Fukuda; Atsushi Tanaka; Koki Nakanishi; Haruyuki Taguchi; Junichi Yoshikawa; Kenei Shimada; Minoru Yoshiyama
Journal:  JACC Cardiovasc Imaging       Date:  2013-03-14

7.  Beyond Coronary Calcification, Family History, and C-Reactive Protein: Cholesterol Efflux Capacity and Cardiovascular Risk Prediction.

Authors:  Purav Mody; Parag H Joshi; Amit Khera; Colby R Ayers; Anand Rohatgi
Journal:  J Am Coll Cardiol       Date:  2016-05-31       Impact factor: 24.094

8.  Cholesterol Efflux Capacity, High-Density Lipoprotein Particle Number, and Incident Cardiovascular Events: An Analysis From the JUPITER Trial (Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin).

Authors:  Amit V Khera; Olga V Demler; Steven J Adelman; Heidi L Collins; Robert J Glynn; Paul M Ridker; Daniel J Rader; Samia Mora
Journal:  Circulation       Date:  2017-04-27       Impact factor: 29.690

9.  High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age.

Authors:  Annelies W E Weverling-Rijnsburger; Iris J A M Jonkers; Eric van Exel; Jacobijn Gussekloo; Rudi G J Westendorp
Journal:  Arch Intern Med       Date:  2003-07-14

10.  Coronary calcium as a predictor of coronary events in four racial or ethnic groups.

Authors:  Robert Detrano; Alan D Guerci; J Jeffrey Carr; Diane E Bild; Gregory Burke; Aaron R Folsom; Kiang Liu; Steven Shea; Moyses Szklo; David A Bluemke; Daniel H O'Leary; Russell Tracy; Karol Watson; Nathan D Wong; Richard A Kronmal
Journal:  N Engl J Med       Date:  2008-03-27       Impact factor: 91.245

View more
  10 in total

1.  Rationale and design of the expanded combination of evolocumab plus empagliflozin in diabetes: EXCEED-BHS3 trial.

Authors:  Ikaro Breder; Jessica Cunha Breder; Isabella Bonilha; Daniel B Munhoz; Sheila T Kimura Medorima; Daniela C Oliveira; Helison R do Carmo; Camila Moreira; Anatol Kontush; Francesca Zimetti; Ilaria Zanotti; Luiz Sergio F Carvalho; Wilson Nadruz; Elza Muscelli; Thiago Quinaglia; Andrei C Sposito
Journal:  Ther Adv Chronic Dis       Date:  2020-09-28       Impact factor: 5.091

2.  Reverse Cholesterol Transport and Atherosclerosis.

Authors:  Anand Rohatgi
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-01       Impact factor: 8.311

3.  High-density lipoprotein cholesterol and arterial calcification in midlife women: the contribution of estradiol and C-reactive protein.

Authors:  Gretchen Swabe; Karen Matthews; Maria Brooks; Imke Janssen; Norman Wang; Samar R El Khoudary
Journal:  Menopause       Date:  2020-12-21       Impact factor: 3.310

Review 4.  Unravelling HDL-Looking beyond the Cholesterol Surface to the Quality Within.

Authors:  Sarina Kajani; Sean Curley; Fiona C McGillicuddy
Journal:  Int J Mol Sci       Date:  2018-07-06       Impact factor: 5.923

Review 5.  Vulnerable Plaque, Characteristics, Detection, and Potential Therapies.

Authors:  Anouar Hafiane
Journal:  J Cardiovasc Dev Dis       Date:  2019-07-27

6.  HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research.

Authors:  Anand Rohatgi; Marit Westerterp; Arnold von Eckardstein; Alan Remaley; Kerry-Anne Rye
Journal:  Circulation       Date:  2021-06-07       Impact factor: 39.918

Review 7.  Coagulatory Defects in Type-1 and Type-2 Diabetes.

Authors:  Amélie I S Sobczak; Alan J Stewart
Journal:  Int J Mol Sci       Date:  2019-12-16       Impact factor: 5.923

8.  HDL cholesterol efflux capacity is inversely associated with subclinical cardiovascular risk markers in young adults: The cardiovascular risk in Young Finns study.

Authors:  Monika Hunjadi; Claudia Lamina; Patrick Kahler; Tamara Bernscherer; Jorma Viikari; Terho Lehtimäki; Mika Kähönen; Mikko Hurme; Markus Juonala; Leena Taittonen; Tomi Laitinen; Eero Jokinen; Päivi Tossavainen; Nina Hutri-Kähönen; Olli Raitakari; Andreas Ritsch
Journal:  Sci Rep       Date:  2020-11-05       Impact factor: 4.379

Review 9.  High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives.

Authors:  Maria Pia Adorni; Nicoletta Ronda; Franco Bernini; Francesca Zimetti
Journal:  Cells       Date:  2021-03-05       Impact factor: 7.666

10.  Cholesterol mass efflux capacity and risk of peripheral artery disease: The Multi-Ethnic Study of Atherosclerosis.

Authors:  Parveen K Garg; Neal W Jorgensen; Robyn L McClelland; Matthew Allison; James H Stein; Laurent Yvan-Chavret; Alan R Tall; Steven Shea
Journal:  Atherosclerosis       Date:  2020-02-15       Impact factor: 5.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.